<DOC>
	<DOCNO>NCT00662077</DOCNO>
	<brief_summary>This project will determine incidence osteoporosis population HIV-infected patient assess efficacy security ibandronate , whose efficacy post-menopausal woman already prove .</brief_summary>
	<brief_title>Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort</brief_title>
	<detailed_description>The low bone mineral density describe patient HIV-infection meant increase long term complication . Nevertheless , could involve increase associate co-mordibity future , take care general population osteoporosis increase 4 time pathologic fracture risk . That 's necessary know real prevalence osteoporosis population patient real dimension problem define . This project will determine incidence osteoporosis population HIV-infected patient assess efficacy security ibandronate , whose efficacy post-menopausal woman already prove . If quarterly use endovenous ibandronate obtains equivalent result obtain oral weekly alendronate study population , use would justify posology benefit . The monthly quarterly administration improve compliance patient recieving big quantity drug , HIV infect patient probably treat life . Moreover , elimination renal absence interaction antiretroviral drug mades ibandronate promising alternative . Finally , 's risk digestive intolerance parenteral administration well posology oral bifosfonates .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . 18 year old elder . 2 . Documented HIV1 infection , without antiretroviral treatment . 3 . Presence WHO osteoporosis criterion , define tscore 2.5 lumbar , hip and/or trochanter . ( DEXA last 6 month need ) 4 . Willing follow study protocol . 5 . Informed Consent signature . 1 . In woman , pregnancy breastfeeding . 2 . Other possible cause secondary osteoporosis . 3 . Creatinin 2.3mg/mL 4 . Glomerular filter le 50 mL/min ( estimate MDRD ) 5 . Alendronate treatment last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>bifosfonates</keyword>
	<keyword>ibandronate</keyword>
</DOC>